(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
FBI arrests Brian Cole Jr. in Jan. 6 pipe bomb investigation, ending 5-year hunt - 2One perk to marrying Richard Marx later in life? 'We don't have time' for stupid arguments, says Daisy Fuentes.
- 3Car Investigation: A Survey of \Past the Outside\ Car
- 4Which Kind of Pet Makes the Incomparable Buddy?
- 5Scientists solve the mystery of 'impossible' merger of 'forbidden' black holes
- Disability rights activist and author Alice Wong dies at 51
- Black Friday streaming deals 2025: Grab the Disney+ Hulu bundle for only $5 and save over 60%
- Tech Patterns: Devices That Will Shape What's to come
- 5 Pizza Fixings That Characterize Your Character
- Extravagance SUVs for Seniors: Solace, Innovation, and Security
- Best bar-b-que Style: Which One Is Your Number one?
- As world leaders enter climate talks, people in poverty have the most at stake
- The Specialty of Do-It-Yourself Home Style: Change Your Space
- Monetary Strength: Get ready for Life's Unforeseen Difficulties
